Abstract YO32
Case summary
Prostatic rhabdomyosarcoma in adult is a uncommon disease of adult. There are few cases reported as adult rhabdomyosarcoma of prostate. Most of the cases present with advanced stage. Modality of treatment vary from that of pediatric counterpart. Moreover stage wise treatment for adult disease are not well defined. We presented a young adult case of rhabdomyosarcoma presented with acute retention of urine and severe lower abdominal pain. After evaluation we thought of prostatic rhabdomyosarcoma which was later confirmed by IHC study. As the case was metastatic during presentation panel of experts recommend neoadjuvant chemotherapy followed by surgery according to the response of the treatment. There is no clear treatment plan recommendation for this advance stage, but we planned to evaluate Doxorubicin and Ifosphamide regimen for clinical trial. Surprisingly the systemic therapy works and after 3 cycle there was a very small residue persist. After almost complete response we recommended to continue further 3 cycle. Though surgery and radiation therapy Is the mainstay of treatment we can recommend neoadjuvant chemotherapy for metastatic rhabdomyosarcoma of prostate in adult from our clinical experience.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
481P - Updated survival outcomes of the phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small cell lung cancer (KTORG1402)
Presenter: Toshihide Yokoyama
Session: Poster display session
Resources:
Abstract
490P - Outcomes of sequential epidermal growth factor receptor tyrosine (EGFR) tyrosine kinase inhibitor (TKI) therapy in patients with advanced non-small cell lung carcinoma (NSCLC)- a real-world institutional experience
Presenter: Yvonne Ang
Session: Poster display session
Resources:
Abstract
498P - An observational retrospective study to evaluate the incidence of acquired EGFR T790M resistance in NSCLC patients with EGFR mutation following progression after at least one prior EGFR TKI treatment in Taiwan: ARISE study
Presenter: Shang-gin Wu
Session: Poster display session
Resources:
Abstract
501P - Clinical characteristics and efficacy in non-small cell lung cancer patients with EGFR exon 20 insertion and EGFR amplification
Presenter: Xin Gao
Session: Poster display session
Resources:
Abstract
502P - Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced non-small cell lung cancer with uncommon mutations: A multicenter observational study
Presenter: Masaki Kanazu
Session: Poster display session
Resources:
Abstract
482P - Interim analysis from a phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC
Presenter: Filippo De Marinis
Session: Poster display session
Resources:
Abstract
483P - A phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients with EGFR mutation-positive NSCLC: A biomarker analysis
Presenter: Rafael Rosell
Session: Poster display session
Resources:
Abstract
484P - Activity of afatinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC and baseline brain metastases: Pooled analysis of three large phase IIIb trials
Presenter: Maya Gottfried
Session: Poster display session
Resources:
Abstract
491P - Clinical outcomes of leptomeningeal metastases in EGFR-mutant lung adenocarcinoma
Presenter: Chia-I Shen
Session: Poster display session
Resources:
Abstract
510P - Paclitaxel as continuation maintenance therapy in patients with advanced non-small cell lung cancer
Presenter: Suzy Gohar
Session: Poster display session
Resources:
Abstract